Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors

Accumulating evidence identifies non-genetic mechanisms substantially contributing to drug resistance in cancer patients. Preclinical and clinical data implicate the transcriptional co-activators YAP1 and its paralog TAZ in resistance to multiple targeted therapies, highlighting the strong need for...

Descripción completa

Detalles Bibliográficos
Autores principales: Dieter, Sebastian M., Lovecchio, Domenica, Pataskar, Abhijeet, Zowada, Martina K., Körner, Pierre-René, Khalizieva, Anna, van Tellingen, Olaf, Jäger, Dirk, Glimm, Hanno, Agami, Reuven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355870/
https://www.ncbi.nlm.nih.gov/pubmed/35798875
http://dx.doi.org/10.1038/s41388-022-02400-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355870/
https://www.ncbi.nlm.nih.gov/pubmed/35798875
http://dx.doi.org/10.1038/s41388-022-02400-z

Ejemplares similares